|

Testing Gene PilotLX With Latinx Cancer Patients

RECRUITINGN/ASponsored by Fox Chase Cancer Center
Actively Recruiting
PhaseN/A
SponsorFox Chase Cancer Center
Started2025-05-30
Est. completion2027-05-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
Locations4 sites
View on ClinicalTrials.gov →

NCT06476938

Summary

This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

Self-identified Latinx patients who:

1. diagnosed with solid tumor cancers
2. speak/read English or Spanish;
3. can provide informed consent.

Exclusion Criteria:

Patients with hematologic/liquid cancers (leukemia, lymphoma, multiple myeloma, etc.)

Conditions1

Cancer

Locations4 sites

New Jersey

1 site
MD Anderson Cancer Center at Cooper
Camden, New Jersey, 08103
Andrea Nicholson, MPH856-735-6249nicholson-andrea@CooperHealth.edu

New York

1 site
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Erik Harden212-305-6361eh2828@cumc.columbia.edu

Pennsylvania

2 sites
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Michael J Hall, MD,MS215-728-2861michael.hall@fccc.edu
Temple University Hospital
Philadelphia, Pennsylvania, 19122
Sarah B Bass, PhD, MPH215-204-5110sbass@temple.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.